secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2022-11-18T23:59:59+00:00
Accession:  0001493152-22-032857
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity Q2 FY2023 revenue $2.4M, up 14% sequentially; net loss $4.9M
-----------------------------------------------------------------------

- Revenue $2.4M, up 14% QoQ; gross profit $1.3M (54% margin).
- Net loss $4.9M ($0.094 per share) for quarter ended Sept 30, 2022.
- Bioheart monitor won TIME's Best Inventions 2022; awarded $250K NIH grant.
- Surpassed 2 billion recorded heartbeats for AFib; launched Biocare Cardiac Disease Management Solution.
- Maintained 95%+ customer retention; new distribution partnerships signed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315222032857/0001493152-22-032857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315222032857/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer